hank
Cell therapyexperimentalCOVID-19
Hank is a male given name. It may have been inspired by the Dutch name Henk, itself a short form of Hendrik and thus related to Harry, Harvey, and Henry. — Wikipedia
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2019 (NCT03853317)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaHank ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04144335 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2019 | University of Minnesota |
| NCT03853317 | Phase 2 | Mar 31, 2019 | NantCell, Inc., NantWorks |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NantCell, Inc. | For profit | 1 | 0 | 1 | 2019 |
| NantWorks | For profit | 1 | 1 | 1 | 2019 |
| University of Minnesota | Academic/Hospital | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1